CSBTF Stock Kuros Bioscience (CSBTF, $38.15) RSI Indicator left the overbought zone on November 28, 2025

GET DAILY SIGNALS

Get AI intraday signals

CSBTF - Kuros Bioscience Ltd.

RSI signal

View

Odds of DOWN Trend

Price: $38.15

Daily change: +$1.9 (+5.24%)

Daily volume: 1K

Capitalization: $1.5B

Industry: Medical/Nursing Services

This is a signal that CSBTF's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options. A.I.dvisor looked back and found 29 similar cases where CSBTF's RSI Indicator left the overbought zone, and in of them led to a successful outcome. Odds of Success:

Aroon Indicator for CSBTF shows an upward move is likely

CSBTF's Aroon Indicator triggered a bullish signal on October 28, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 151 similar instances where the Aroon Indicator showed a similar pattern. In of the 151 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 27 cases where CSBTF's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 19, 2025. You may want to consider a long position or call options on CSBTF as a result. In of 33 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CSBTF just turned positive on November 28, 2025. Looking at past instances where CSBTF's MACD turned positive, the stock continued to rise in of 23 cases over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CSBTF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.576) is normal, around the industry mean (63.271). P/E Ratio (0.000) is within average values for comparable stocks, (37.178). CSBTF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.671). CSBTF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.018). P/S Ratio (11.403) is also within normal values, averaging (35.282).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.